Kenneth E. Pengel - Publications

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society

Published: December 07, 2016

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.

Journal: PloS one

Published: November 12, 2016

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.

Journal: Breast cancer research : BCR

Published: December 02, 2015

The use of radioactive iodine-125 seed localization in patients with non-palpable breast cancer: a comparison with the radioguided occult lesion localization with 99m technetium.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: November 04, 2014

Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 08, 2013

Avoiding preoperative breast MRI when conventional imaging is sufficient to stage patients eligible for breast conserving therapy.

Journal: European journal of radiology

Published: June 24, 2013

Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.

Journal: European journal of nuclear medicine and molecular imaging

Published: February 10, 2013

Fully automated deformable registration of breast DCE-MRI and PET/CT.

Journal: Physics in medicine and biology

Published: February 02, 2013

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: July 23, 2012